Skip to content
OpenCapital
Get started

Medtronic MDT Derivative, Fair Value, Amount Offset Against Collateral, Net

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$101.86B-3.8%
Enterprise value$129.12B-3.2%
P/E21.2×-1.5×
P/S2.8×-0.4×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:DerivativeFairValueAmountOffsetAgainstCollateralNet.

The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medtronic's derivative, fair value, amount offset against collateral, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medtronic's derivative, fair value, amount offset against collateral, net?
Medtronic (MDT) reported derivative, fair value, amount offset against collateral, net of $264M in Q4 2025.
How has Medtronic's derivative, fair value, amount offset against collateral, net changed year-over-year?
Medtronic's derivative, fair value, amount offset against collateral, net decreased by 58.0% year-over-year, from $629M to $264M.
What is the long-term trend for Medtronic's derivative, fair value, amount offset against collateral, net?
Over 4 years (2021 to 2025), Medtronic's derivative, fair value, amount offset against collateral, net has grown at a -27.0% compound annual growth rate (CAGR), from -$148M to $42M.